Muscular Dystrophy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Muscular Dystrophy stocks.

Muscular Dystrophy Stocks Recent News

Date Stock Title
Jul 1 PTCT PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug
Jul 1 BNTC Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
Jun 28 PTCT Biggest stock movers today: PLUG, NKE, DJT, and more
Jun 28 PTCT PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
Jun 28 PTCT PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
Jun 28 PTCT PTC drops as EU panel declines to recommend Translarna marketing renewal
Jun 28 PTCT CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
Jun 27 SMMT Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
Jun 27 SRPT Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Jun 27 TRDA With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors
Jun 27 WVE Analysts Are Betting On Wave Life Sciences Ltd. (NASDAQ:WVE) With A Big Upgrade This Week
Jun 26 SRPT Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.
Jun 26 SRPT Sarepta cut to Neutral at Citi on risks to valuation
Jun 26 WVE Update: WAVE Life Sciences Discloses 'Positive' Phase 1b/2a Data From Huntington's Disease Treatment But Shares Fall on Neurofilament Concern
Jun 26 SRPT Insider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
Jun 25 WVE What's Going On With Wave Life Sciences Stock On Tuesday?
Jun 25 WVE Wave jumps on trial data for Huntington’s disease therapy
Jun 25 WVE Wave, with new data, plots path forward for Huntington’s drug
Jun 25 WVE Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Muscular Dystrophy

Muscular dystrophy (MD) is a group of muscle diseases that results in increasing weakening and breakdown of skeletal muscles over time. The disorders differ in which muscles are primarily affected, the degree of weakness, how fast they worsen, and when symptoms begin. Many people will eventually become unable to walk. Some types are also associated with problems in other organs.The muscular dystrophy group contains thirty different genetic disorders that are usually classified into nine main categories or types. The most common type is Duchenne muscular dystrophy (DMD) which typically affects males beginning around the age of four. Other types include Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy. They are due to mutations in genes that are involved in making muscle proteins. This can occur due to either inheriting the defect from one's parents or the mutation occurring during early development. Disorders may be X-linked recessive, autosomal recessive, or autosomal dominant. Diagnosis often involves blood tests and genetic testing.There is no cure for muscular dystrophy. Physical therapy, braces, and corrective surgery may help with some symptoms. Assisted ventilation may be required in those with weakness of breathing muscles. Medications used include steroids to slow muscle degeneration, anticonvulsants to control seizures and some muscle activity, and immunosuppressants to delay damage to dying muscle cells. Outcomes depend on the specific type of disorder.Duchenne muscular dystrophy, which represents about half of all cases of muscular dystrophy, affects about one in 5,000 males at birth. Muscular dystrophy was first described in the 1830s by Charles Bell. The word "dystrophy" is from the Greek dys, meaning "difficult" and troph meaning "nourish". Gene therapy, as a treatment, is in the early stages of study in humans.

Browse All Tags